Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responses
Piki, Emilia; Dini, Alice; Rantanen, Frida; Bentz, Franziska; Paavolainen, Lassi; Barker, Harlan; Raivola, Juuli; Hirasawa, Akira; Kallioniemi, Olli; Murumägi, Astrid; Ungureanu, Daniela (2024-12-19)
Piki, Emilia
Dini, Alice
Rantanen, Frida
Bentz, Franziska
Paavolainen, Lassi
Barker, Harlan
Raivola, Juuli
Hirasawa, Akira
Kallioniemi, Olli
Murumägi, Astrid
Ungureanu, Daniela
19.12.2024
Molecular Therapy: Oncology
200903
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-2024120410744
https://urn.fi/URN:NBN:fi:tuni-2024120410744
Kuvaus
Peer reviewed
Tiivistelmä
Patients with ovarian cancer, especially the high-grade serous ovarian cancer (HGSOC) subtype, face poor prognosis due to late diagnosis and treatment resistance. Owing to the high heterogeneity of HGSOC, identifying the origin of the disease and optimal treatments is difficult. Here, we characterized two primary immortalized human ovarian cell lines, human ovarian surface epithelium (HOSE)1C and HOSE2C, comparing their molecular profiling with representative HGSOC cells. We identified molecular features associated with normal and malignant phenotype of ovarian cells by applying single-cell transcriptomics, high-content image-based cell painting, and high-throughput drug testing. Our findings reveal distinct transcriptomic and morphological profiles for the two HOSEs, with a stromal phenotype. Moreover, their responses to the tumor microenvironment differ, exemplified by STAT1 and GREM1 upregulation in HOSE1C and HOSE2C, respectively. We identified selective activation of ERK/MEK targeted inhibitors in cancer cells compared to HOSEs. This study offers insights into the normal and malignant ovarian cells, shedding light on cancer development and drug responses.
Kokoelmat
- TUNICRIS-julkaisut [20689]